English (UK)
中文版Enosi Life Sciences 
h michael shepard
CSO and CEOExoProTher Medical LTD 
The company has been funded by private investors. We are currently working on shaping our next funding round.
Lana Volokh
PhDFocus-X Therapuetics
Fa Liu
CEO
GATTACO Inc.
Michael McNeely
Pres/CEO
Genervon Biopharmaceuticals
Genervon Biopharmaceuticals discovered an endogenous embryonic-stage regulator, Motoneuronotrophic Factor (MNTF), and developed from it the pleiotropic drug GM6. Chronic inflammation is associated with a broad spectrum of neurodegenerative diseases related to aging. GM6 simultaneously modulates multiple biological mechanisms (MOA) in the CNS and immune system to increase neurogenesis and lower inflammation. The MOAs include oxidative Stress, protein aggregation, kinase dysfunction, cholinergic signaling, extracellular matrix stability, and intrinsic apoptosis. GM6 reduces Beta Amyloid and phosphorylated tau in AD, reduces SOD1 in ALS, and reduces inflammation in animal models. GM6 passes through the blood-brain barrier and has good drug-like properties. GM6 has been studied in a Phase 1 and two Phase 2A trials and was shown to be safe and tolerable with positive clinical outcomes and favorable shifts in biomarkers SOD1, Tau and TDP43 in patients. A complete CMC package is ready for technology transfer.
Dorothy Ko
Chief Operating OfficerGenerys Biopharmaceuticals
for multiple psychiatric disorders with unmetmedical needs.
The parent company, Generys Therapeutics Corp.
headquartered in Rep. of Korea is a controlled foreign
company (US IRS code).
Tong Lee
CEO
Glenpharma AB 
Glenpharma AB is a small privately owned research spin-off from Pfizer-Pharmacia, formed in Sweden in 2002 to exploit novel technology patented by its founders.
We offer patented synergistic combinations of biopolymers for
a) accelerated repair of acute tendon /ligament injuries in human applications ( such as sprained ligaments / tendons in shoulder, elbow, knee, ankle, etc , in both sports injury scenarios and in the elderly ) , or in veterinary indications (e.g. high performance horses) . The product accelerates healing at least 3 times faster than the normal healing process.
b) for prevention of unwanted adhesions between tissues after major thoracic, abdominal , fertility or orthopedic surgery. In studies on prevention of difficult adhesions after cardiac surgery, for example, adhesion scores were < 10% of those in control groups.
c) for effective control of acute pain in advanced joint disease (osteo-arthritis (OA) . Clinical documentation in advanced OA indicates that onset of pain relief is much faster and of longer duration than current standards for viscosupplementation.
Each of the above biopolymer "viscous fluid implants" are also ideal drug delivery media for treatment of ancillary complications.
All component biopolymers are well documented APIs, i.e. without the toxicty and other regulatory issues generally associated with "New Chemical Entities". Glenpharma´s current patent protection covers most major international markets including USA, Europe and P R China.
Glenpharma is primarily seeking Chinese partners for out-licensing within the fields of orthopedics or major surgery.. If neccessary , we can offer contract-manufacturing options in Europe if not available in China.
Senior Scientist Peter Buckley
CEO
GlycoSeLect Ltd 
Our company develops and manufactures technology and applications for glycoprotein separation and analysis. We are focussed on the biopharmaceutical industry. We also have customers in medical diagnostic and cosmetic companies.
Our facility is based on the campus of Dublin City University in Ireland.
We have developed an extensive network of contacts not only customers but also opinion leaders in glybiology.
Responsive Web Design powered by 